Jan van der Laan
Assistant professor / guest
- Name
- Dr. J.W. van der Laan
- Telephone
- +31 6 5275 6424
- jw.vd.laan@cbg-meb.nl
Dr. Jan-Willem van der Laan is senior staff member (SOR-RIVM) at the Division of Drug Discovery & Safety.
More information about Jan van der Laan
PhD Candidates
van der Laan, Jan Willem, PhD
In 1980 Jan Willem van der Laan joined the National Institute for Public Health and the Environment (RIVM, Bilthoven) as a biochemist and pharmacologist on CNS targets. In 1990 he became assessor Pharmacology and Toxicology of Human Pharmaceuticals at the same institute. Since 2011 he serves in the same role the Medicines Evaluation Board, located in Utrecht, the Netherlands. He is chair of the EMA/CHMP Safety Working Party since 2012. His contributions to the International Council on Harmonization started in 1993 on Carcinogenicity Testing. In 2012 the discussions on this topic have been restarted to reduce the number of 2-yr studies in rodents, and Jan Willem is Regulatory Chair on this process.
Jan Willem van der Laan is leading a project on “Mechanistic differentiation of nongenotoxic carcinogenic pharmaceuticals and their human relevance”, funded by the Medicines Evaluation Board, on which project Britt Duijndam is working as a Ph.D student.
Projects
- Pro-mitogenic effects of insulin analogues and mammary gland tumor development
Courses
- Caput: "Regulation of Drug Safety (RDS)"
Assistant professor / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Braak S.J. ter, Siezen C.L., Lee J.S., Rao P., Voorhoeve C., Ruppin E., Laan J.W. van der & Water B. van de (2017), Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production, Breast cancer research 19: 14.
- Braak S.J. ter, Siezen C.L.E., Speksnijder E.N., Koedoot E., Steeg H. ter, Salvatori D.C.F., Water B. van de & Laan J.W. van der (2015), Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53(R270H/+)WAPCre mouse model, Breast cancer research 17: 14.
- Dempster M., Siezen K., Braak S.J. ter, Brink W.J. van den, Emerenciana A., Bellanti F., Duijnhoven R.G., Kwa M. & Laan J.W. van der (2015), Carcinogenicity of Biopharmaceuticals. In: Graziano M.J. & Jacobson-Kram D. (Eds.), Genotoxicity and Carcinogenicity Testing of Pharmaceuticals. Cham: Springer International Publishing. 125-157.
- Bronsveld H.K., Braak B. ter, Karlstad O., Vestergaard P., Starup-Linde J., Bazelier M.T., Bruin M.L. de, Boer A. de, Siezen C.L.E., Water B. van de, Laan J.W. van der & Schmidt M.K. (2015), Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence, Breast cancer research 17: 100.
- Braak B. ter, Wink S., Koedoot E., Pont C., Siezen C., Laan J.W. van der & Water B. van de (2015), Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells, Breast cancer research 17: 97.